Threshold Pharmaceuticals
Threshold developed evofosfamide, a drug switched on only in the oxygen-starved parts of tumours; two phase 3 trials in pancreatic cancer and sarcoma failed in 2015 and the company merged away.
Overview
Threshold Pharmaceuticals, founded in 2001 in San Francisco, pursued hypoxia-activated prodrugs, chiefly evofosfamide (TH-302), a bromo-isophosphoramide mustard released in hypoxic tumour tissue and partnered with Merck KGaA. The MAESTRO trial in pancreatic cancer and the TH CR-406 trial in soft tissue sarcoma both missed their survival endpoints in 2015; Threshold later merged with Molecular Templates. Its trials remain on ClinicalTrials.gov under Threshold as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyCEBIOTEX
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.
- CompanyAdvenchen Laboratories
Shares Pivotal (registrational) trial, Clinical trial, Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.